Enhancing Equitable Health Product Roll-out in Low- and Middle-Income Countries
Strategies to enhance equitable access to health products in low- and middle-income countries will be discussed at the AIDS 2022 conference, focusing on key factors such as availability, acceptability, affordability, accessibility, and quality. The Medicines Patent Pool aims to increase access to in
0 views • 14 slides
Impact of Antiretroviral Treatment on Weight and Obesity in HIV Patients
Dolutegravir (DTG) treatment has shown associations with weight gain and clinical obesity, particularly in black individuals and women. In contrast, tenofovir disoproxil fumarate (TDF) is linked to lower body weight compared to other treatments. Trials like ADVANCE and NAMSAL have provided insights
0 views • 31 slides
Dolutegravir-Lamivudine Dual Therapy in ARV-Naïve HIV Patients: 48-Week Results of PADDLE Trial
The PADDLE trial evaluated the efficacy, safety, and tolerability of a Dolutegravir-Lamivudine regimen as initial therapy in HIV-infected, treatment-naïve patients. This pilot study demonstrated comparable viral load changes to triple therapy, supporting the use of this dual regimen. The study desi
0 views • 13 slides
Based on the given content, here is the requested information: "Advances in Antiretroviral Therapy: Insights from Clinical Cases
This session featured a case-based panel discussion by Dr. Michael S. Saag on selecting antiretroviral therapy for specific patient profiles, including those coinfected with hepatitis B virus and HIV, pregnant partners of HIV-seropositive patients, and individuals experiencing chronic kidney disease
0 views • 11 slides
DTG Monotherapy in Early HIV-1 Infection: Study Overview
Study investigating the efficacy of dolutegravir (DTG) monotherapy in early HIV-1 infection showed non-inferiority compared to standard combination antiretroviral therapy (cART). The EARLY-SIMPLIFIED study involved 68 patients on DTG monotherapy and 33 on cART, with both groups achieving HIV RNA sup
0 views • 6 slides
Tuberculosis as a Risk Factor for Viral Non-Suppression in Patients Switched to Dolutegravir-Based Therapy
The study investigates the impact of incident tuberculosis on viral non-suppression among patients transitioning to Dolutegravir-based therapy in Zambia. It aims to identify factors associated with viral non-suppression and describe clinical outcomes in the context of tuberculosis occurrence. The re
0 views • 13 slides